Notably, the inhibition of GSK-3α kinase function did not stabilize β-catenin in acute myeloid leukaemia cells, providing a feasible strategy to develop paralog-selective GSK-3α inhibitors enforceable to cancer therapy [247]. The gene discussed is GSK3A; the disease is cancer.